Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aminooxyacetic acid is a small molecule inhibitor of pyridoxal phosphate-dependent enzymes, most notably 4‑aminobutyrate aminotransferase (GABA transaminase or GABA-T). By inhibiting this enzyme, it increases gamma‑aminobutyric acid (GABA) levels in tissues. It also inhibits aspartate aminotransferase and other PLP-dependent enzymes by forming oxime-type complexes with the cofactor. Aminooxyacetic acid has been studied as a nootropic agent and anticonvulsant, and was previously investigated for Huntington's disease and tinnitus due to its effects on GABA metabolism. However, clinical use is limited by frequent side effects such as drowsiness, ataxia, seizures, psychosis, nausea, and dizziness at higher doses[1][2][3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aminooxyacetic acid.